COMBINATION OF CAMOSTAT MESILAT AND UMIFENOVIR HYDROCHLORIDE WITH PROTON PUMP INHIBITORS
The present invention is the combination of Camostat Mesylate, Umifenovir Hydrochloride and 40-80 mg Esomeprazole Magnesium Trihydrate, which is used for the prevention, delay or treatment of COVID- 19 disease. In the combination of the invention, Camostat Mesylate, Umifenovir Hydrochloride and Esomeprazole Magnesium Trihydrate may be present in separate pharmaceutical compositions or in the same pharmaceutical composition. The COVID-19 patients to whom the inventive combination will be administered will preferably be uncomplicated but probable or definitively diagnosed COVID-19 patients..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 29. Juni Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
TASKIN TAMBAY [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-06-29, Last update posted on www.tib.eu: 2023-10-19, Last updated: 2023-10-27 |
|---|
| Patentnummer: |
WO2023121629 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017635004 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017635004 | ||
| 003 | DE-627 | ||
| 005 | 20231027104241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017635004 | ||
| 035 | |a (EPA)WO2023121629 | ||
| 035 | |a (EPA)85116928 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a TASKIN TAMBAY |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COMBINATION OF CAMOSTAT MESILAT AND UMIFENOVIR HYDROCHLORIDE WITH PROTON PUMP INHIBITORS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-06-29, Last update posted on www.tib.eu: 2023-10-19, Last updated: 2023-10-27 | ||
| 520 | |a The present invention is the combination of Camostat Mesylate, Umifenovir Hydrochloride and 40-80 mg Esomeprazole Magnesium Trihydrate, which is used for the prevention, delay or treatment of COVID- 19 disease. In the combination of the invention, Camostat Mesylate, Umifenovir Hydrochloride and Esomeprazole Magnesium Trihydrate may be present in separate pharmaceutical compositions or in the same pharmaceutical composition. The COVID-19 patients to whom the inventive combination will be administered will preferably be uncomplicated but probable or definitively diagnosed COVID-19 patients. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a DEGIM ISMAIL TUNCER |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 29. Juni |
| 773 | 1 | 8 | |g year:2023 |g day:29 |g month:06 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/85116928/publication/WO2023121629A1?q=WO2023121629 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 29 |c 06 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 29 |c 06 | ||